Nuvalent bags $135M to trial resistance-beating kinase inhibitors in lung cancer

Nuvalent has raised $135 million to take ROS1 and ALK kinase inhibitors into the clinic. The series B, which comes months after Nuvalent disclosed a $50 million round, sets Nuvalent up to study drugs designed to improve on products such as Roche’s Alecensa and Pfizer’s Xalkori.